ICER will review elagolix (AbbVie) for management of endometriosis with associated pain.
Communication & Creative Media (CCM) Building
375 Maple Street
Burlington, VT 05401
The New England CEPAC will review ICER's report on elagolix for endometriosis.
Open to public comment until 5pm ET on May 31, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.